Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 49/100

Redhill Biopharma Ltd at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 12:00PM GMT
Release Date Price: €152.8
Operator

Ladies and gentlemen, welcome to today's RedHill conference call. I would now like to turn the call over to your host, Mr. Prasad. Sir, please go ahead.

Balaji V. Prasad;Dror Ben;Asher
Barclays Bank PLC, Research Division - Director

Thank you. Good morning, everyone. Thank you for dialing in. My name is Balaji Prasad. I cover specialty pharma for Barclays. So owing to the special circumstances we are in, this is a virtual health care conference and the continuation of day 2 now.

Starting with today's session, we have Dror Ben-Asher, the CEO of RedHill Biopharma, an up-and-coming GI player, which has 3 FDA-approved products officially. This is the recent announcement of the deal with AstraZeneca.

The format will be a presentation from Dror, and there will be no Q&A session owing to this virtual presentation. And at the end of it, of course, RedHill will be hosting one-on-one meetings during the course of the day, virtual one-on-one meetings.

And with that, I invite Dror to take over.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot